Difference between revisions of "Tamoxifen (Nolvadex)"
(updated content) |
m (→References) |
||
| Line 24: | Line 24: | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:Uterine cancer medications]] | [[Category:Uterine cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1977]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 19:05, 5 June 2016
Also known as Istubal, Soltamox, or Valodex.
General information
Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type. Tamoxifen has estrogen antagonist properties in breast tissue. It has estrogen agonist properties in bone, helping to decrease bone resorption, but in contrast to Raloxifene (Evista), it also has agonist properties in uterine tissue.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Tamoxifen (Nolvadex) package insert PDF pages 32-37[1]
- Tamoxifen (Nolvadex) patient drug information (Chemocare)[3]
- Tamoxifen (Nolvadex) patient drug information (UpToDate)[4]